The Prognostic Value of Frailty in a Transcatheter Mitral Valve-in-Valve Cohort
•MViV is effective for managing degenerative bioprosthetic mitral valves.•Frailty is a strong predictor of outcome for cardiac interventions.•Increasing frailty is predictive of poor outcomes post-MViV.
Authors
- Jyothy Puthumana
- Akhil Narang (ORCID: https://orcid.org/0000-0001-9248-808X)
- Abigail S. Baldridge (ORCID: https://orcid.org/0000-0002-1573-0554)
- James D. Flaherty (ORCID: https://orcid.org/0000-0002-6707-8414)
- Chen Chen (ORCID: https://orcid.org/0009-0005-9936-0923)
- Vinesh Appadurai (ORCID: https://orcid.org/0000-0002-4883-2979)
- S. Chris Malaisrie (ORCID: https://orcid.org/0000-0002-0704-0334)
- Patrick McCarthy (ORCID: https://orcid.org/0000-0003-0285-5996)
- J. D. Thomas
- Charles J. Davidson
- Zhiying Meng (ORCID: https://orcid.org/0009-0003-9875-4467)
Institutions
- Northwestern University (US)
- The University of Queensland (AU)
- Cardiovascular Institute of the South (US)
Publication Details
- Journal
- Structural Heart
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1016/j.shj.2025.100462
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Northwestern University
- Feinberg School of Medicine